BMS IM101-823 (Autoimmune Hepatitis) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about how the study drug (Abatacept) effects the health of people that have had a liver transplant and have autoimmune hepatitis.

What is the Condition Being Studied?

Abatacept for Autoimmune Hepatitis

Who Can Participate in the Study?

Adults that:
- Have had a liver transplant
- Have been diagnosed with autoimmune hepatitis

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Get the study (Abatacept) drug once a week for 6 months (up to a year if it is helping)
- Complete follow-up visits for 1 year after stopping the study drug

Study Details

Full Title
Abatacept for treatment of recurrent or de novo autoimmune hepatitis
Principal Investigator
Kidney/Pancreas Transplant Surgeon
Protocol Number
IRB: PRO00102357
NCT: NCT04203875
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698